# VTX002 Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis

> **NCT05156125** · PHASE2 · TERMINATED · sponsor: **Oppilan Pharma Ltd** · enrollment: 213 (actual)

## Conditions studied

- Colitis, Ulcerative

## Interventions

- **DRUG:** VTX002
- **DRUG:** VTX002
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05156125
- **Lead sponsor:** Oppilan Pharma Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-11-30
- **Primary completion:** 2023-08-30
- **Final completion:** 2025-03-13
- **Target enrollment:** 213 (ACTUAL)
- **Why stopped:** The Induction and Long-Term Extension Periods were completed and analyzed as planned. The Sponsor decided to terminate clinical conduct in the Open-Label Extension Period. The decision to terminate the study was not due to safety concerns.
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05156125

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05156125, "VTX002 Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05156125. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*